Cash resources totaled approximately $225 million as of June 30, 2025 Cash resources totaled approximately $225 million as of June 30, 2025
Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties Abeona will receive a license payment and potential development, regulatory, and sales
CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awar
CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it was added as a member of the U.S. small-cap Russell 2000® Index and the broad-market Russe
- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and ri
Squarepoint Ops LLC bought a new position in Abeona Therapeutics Inc (NASDAQ:ABEO – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securitie
Abeona's ZEVASKYN approval and a $3.1 million price point are undervalued by the market, especially after a $152 million PRV sale bolstered cash reserves. Conservative launch modeling, including risk-
CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awar
CLEVELAND, May 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Ph.D., Chief Executive Officer, and Madhav Vasanthavada, Ph.D., Chief Commercial
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Greg Gin - Vice President-Investor Relations and Communications Vish Seshadri - Ch
- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand p
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. -
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. -
CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priorit
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE